Pouchitis After J-Pouch Surgery: Causes, Treatments and Outlook

Table of Contents

1. What the J-Pouch Is and Why It Can Become Inflamed
2. How Often Pouchitis Happens
3. Acute, Recurrent and Chronic Pouchitis
4. Symptoms and How Pouchitis Is Confirmed
5. What Is Known About the Causes
6. Primary Sclerosing Cholangitis and Other Risk Factors
7. What the Antibiotic Trials Show
8. Vedolizumab and the EARNEST Trial
9. Other Biologic Medicines
10. What the Probiotic Trials Found
11. Stool Transplant Trials
12. Crohn's-Like Disease of the Pouch
13. Pouch Failure and the Long-Term Outlook
14. Key Research Papers
15. Connections
16. Featured Videos

What the J-Pouch Is and Why It Can Become Inflamed

The small intestine normally moves its contents along rather than storing them. Once a section of it is folded into a pouch and asked to do the job of the rectum, it holds stool and the bacteria that come with it. In some people, the lining of that pouch becomes inflamed.

The International Ileal Pouch Consortium, an expert panel that wrote consensus guidelines on pouch disorders in 2021, describes the operation as an option for most people with ulcerative colitis or familial adenomatous polyposis (an inherited condition that fills the colon with polyps) who need their colon removed. The panel notes that a pouch substantially improves health-related quality of life, but that the surgery is linked, directly or indirectly, to structural, inflammatory and functional problems. It also notes that the operation does not completely remove the risk of cancer, that people with pouches often have inflammatory conditions elsewhere in the body, and that the condition of a pouch can change over time.

Pouchitis is the inflammatory problem in that list. A separate condition, cuffitis, affects the short strip of rectal lining that is sometimes left behind where the pouch is joined; it is described on the surgery decisions page. A third, Crohn's-like disease of the pouch, is covered further down this page.

Back to Table of Contents

How Often Pouchitis Happens

The figures vary with how long people are followed and how pouchitis is defined, but every source agrees that it is common.

• The 2019 Cochrane review of pouchitis treatment and the authors of the 2023 EARNEST trial both state that pouchitis occurs in about half of people who have a J-pouch made for ulcerative colitis.
• A 2025 review describes pouchitis as affecting almost one half of patients in the first 10 years after surgery.
• A 2017 review in the journal Alimentary Pharmacology and Therapeutics gives an incidence of 40% at 5 years.
• A surgical series of 198 people, followed for a mean of 64 months, found pouchitis in 64 (32%). In 70% of those who developed it, the first episode came within the first year.
• A population-based study of 233 Danish people with ulcerative colitis who had a pouch made between 1993 and 2021 found that 118 (50.6%) had at least one episode.

A second Danish study, covering every person in the country who had the operation for ulcerative colitis between 1996 and 2018 (1,664 people), found that pouchitis has become more common over time. The share who developed it within 2 years of surgery rose from 40% among those operated on in 1996–2000 to 55% among those operated on in 2015–2018. After adjusting for sex, age and socioeconomic status, people operated on in the most recent period had a hazard ratio of 1.57 compared with the earliest period. The authors describe this as a 15% absolute and 38% relative increase and state that the reasons need further research.

Back to Table of Contents

Acute, Recurrent and Chronic Pouchitis

Pouchitis is not a single illness with a single course. Doctors and researchers sort it by how it behaves over time and how it responds to antibiotics.

• Acute pouchitis is a single episode. In the 2001 trial of two antibiotics, acute pouchitis was defined as a score of 7 or more on the 18-point Pouchitis Disease Activity Index (PDAI), with symptoms lasting 4 weeks or less.
• Recurrent pouchitis means repeated episodes. A 2025 review in the journal Gut states that antibiotics remain the first treatment but that the majority of patients go on to have further episodes.
• Chronic antibiotic-dependent pouchitis describes people whose symptoms return whenever antibiotics are stopped.
• Chronic antibiotic-refractory pouchitis describes people whose symptoms continue despite antibiotics. A 2021 meta-analysis used the definition of 3 or more episodes a year together with symptoms despite antibiotics.

How many people end up in the chronic groups depends on the source. The EARNEST trial authors state that about one fifth of people who get pouchitis develop chronic pouchitis, and a 2025 review in the Annual Review of Medicine puts chronic pouchitis at about 20% of people with a J-pouch for ulcerative colitis, sorted into antibiotic-dependent, antibiotic-refractory and Crohn's disease-like forms. The 2017 Alimentary Pharmacology and Therapeutics review and the authors of a 2004 probiotic trial each give 10 to 15% of people with pouchitis. A 2021 Finnish trial states that about 5% of patients develop chronic antibiotic-dependent or antibiotic-refractory pouchitis.

The Danish population study counted 519 separate episodes of pouchitis among its 118 affected patients. Of those, 437 (84.2%) were intermittent, 60 (11.6%) were chronic antibiotic-dependent and 22 (4.2%) were chronic antibiotic-refractory.

Back to Table of Contents

Symptoms and How Pouchitis Is Confirmed

A 2025 review lists the main symptoms as more frequent bowel movements, urgency and abdominal discomfort, and notes that they significantly affect quality of life.

Symptoms alone do not settle the question, because, as the International Ileal Pouch Consortium notes, a pouch can have structural and functional problems as well as inflammatory ones. The standard scoring system therefore adds two more pieces of evidence to the symptoms: what the lining looks like through a flexible scope passed into the pouch (pouch endoscopy), and what small tissue samples taken during that look show under the microscope.

The Pouchitis Disease Activity Index

In 1994, researchers at the Mayo Clinic published the Pouchitis Disease Activity Index. It combines three things into one score: symptoms, what the lining looks like through the scope, and what the tissue samples show under the microscope. The full score runs from 0 to 18, with higher numbers meaning more severe pouchitis. The original study was small: it compared 10 people who had a pouch for ulcerative colitis and symptoms of pouchitis with three comparison groups of 5 people each. All 10 people with pouchitis met the new index's criteria, compared with only 1 of the 10 under the older scoring systems, and no person without symptoms met the criteria.

The index became the standard yardstick of the trials described on this page. The 2001 antibiotic trial and the 2004 probiotic trial both used a score of 7 or more to enter people. The EARNEST trial used a modified version that leaves out the microscope findings and runs from 0 to 12; in that trial, remission meant a modified score of 4 or less with a fall of at least 2 points. For the full index, the trial defined remission as a score of 6 or less with a fall of at least 3 points.

Back to Table of Contents

What Is Known About the Causes

No single cause has been proven. The oldest and best-supported idea is that the bacteria living in the pouch drive the inflammation, which is why antibiotics became the first treatment. Several observations fit that idea: antibiotics reduce the activity score in trials, and the probiotic trials described below were built on the theory that changing the pouch's bacteria could keep it quiet.

The bacterial story is not complete, though. A 2025 review in the journal Gut, titled "more than just the microbiota", argues that the high rate of further episodes and the people who do not respond to antibiotics point to a more complex process. The review outlines several mechanisms under study:

• genetic predisposition;
• changes in the pouch's bacteria;
• a weakened lining barrier between the bowel contents and the body;
• an overactive immune response, similar to what is seen in inflammatory bowel disease;
• the possibility that pouchitis involves the whole thickness of the pouch wall rather than only its lining, with non-immune cells such as stromal (supporting) cells helping to keep inflammation going.

The review also points out that the animal models of pouchitis capture only part of the picture and proposes new models built from several cell types. The fact that stool transplants did not work in two randomised trials (see below) also suggests that simply replacing the pouch's bacteria is not enough.

Back to Table of Contents

Primary Sclerosing Cholangitis and Other Risk Factors

Primary sclerosing cholangitis (PSC) is a disease in which the bile ducts in and around the liver become inflamed and scarred. It is strongly linked to ulcerative colitis, and it is the risk factor for pouchitis with the most consistent evidence.

A 2021 meta-analysis pulled together 12 studies covering 4,108 people who had a J-pouch made for ulcerative colitis, 309 of whom also had primary sclerosing cholangitis. Compared with people with ulcerative colitis alone, those who also had primary sclerosing cholangitis were:

• more likely to have any pouchitis: 63% versus 30% (odds ratio 4.21);
• more likely to have chronic pouchitis: 47% versus 15% (odds ratio 6.37);
• more likely to have pouch failure: 10% versus 7% (odds ratio 1.85).

The authors write that the risk of inflammatory complications after the pouch operation has to be weighed against the complications of other operations in this group, and that studies comparing the options are still needed.

Other factors under study

Two meta-analyses published in 2026 looked at many other possible risk factors, and they did not fully agree.

• A meta-analysis of 13 studies (4,264 people, 916 with chronic pouchitis) found chronic pouchitis linked to female sex (odds ratio 1.36), current smoking compared with never smoking (odds ratio 2.46), primary sclerosing cholangitis (odds ratio 2.30), steroid tablets or injections before surgery (odds ratio 1.61), immune-suppressing medicines (odds ratio 1.32) and inflammation outside the bowel, such as in the joints, skin or eyes (odds ratio 3.09). A link with older age did not hold after a correction for publication bias.
• A review of 49 studies on pouchitis of any kind named steroid use before surgery and primary sclerosing cholangitis as the most reliable risk factors. Its pooled analyses found links with primary sclerosing cholangitis (odds ratio 3.52), steroid use before surgery (odds ratio 1.89), tumor necrosis factor (TNF) inhibitor treatment before surgery (odds ratio 1.35) and male sex (odds ratio 1.34). The authors describe smoking, age and sex as still controversial because the evidence conflicts.

The two reviews point in opposite directions on sex, which is one reason the second calls that factor controversial. A 2019 meta-analysis of 22 observational studies (5,128 people) found that inflammation outside the bowel was linked to both chronic pouchitis (odds ratio 2.28) and pouchitis overall (odds ratio 1.96). That surgical series of 198 people found that backwash ileitis (inflammation that extends from the colon into the last part of the small intestine before surgery) and primary sclerosing cholangitis were independent risk factors for chronic pouchitis, with odds ratios of 5.9 and 2.8.

All of these are associations from observational studies. They show who is more likely to develop pouchitis, not that any one factor causes it. More about the bile-duct disease is on the primary sclerosing cholangitis page, and inflammation in the joints, skin and eyes is covered on the extraintestinal manifestations page.

Back to Table of Contents

What the Antibiotic Trials Show

Antibiotics are the usual first treatment. In the Danish population study, antibiotics were used in 89.6% of pouchitis episodes, with ciprofloxacin and metronidazole the most common. Yet the randomised evidence behind them is very small.

Ciprofloxacin compared with metronidazole

The main head-to-head trial, published in 2001, randomised 16 people with acute pouchitis. The trial gave ciprofloxacin 1,000 mg a day (7 people) or metronidazole 20 mg/kg a day (9 people) for 2 weeks. Both drugs lowered the activity score significantly: ciprofloxacin from 10.1 to 3.3 on average, and metronidazole from 9.7 to 5.8. The fall was greater with ciprofloxacin. None of the ciprofloxacin group had side effects, while 3 people in the metronidazole group (33%) had vomiting, a changed sense of taste or temporary nerve symptoms in the hands or feet.

Two systematic reviews read the remission results of this same trial differently. The 2019 Cochrane review reports that all 7 people given ciprofloxacin and 3 of 9 given metronidazole were in remission at 2 weeks. The 2023 review in Alimentary Pharmacology and Therapeutics reports 7 of 7 and 6 of 9, a difference it found could be due to chance. Both rate the evidence as very low certainty.

Other antibiotic and non-antibiotic comparisons

• In one trial in the Cochrane review, 6 of 14 people given metronidazole and 6 of 12 given a budesonide enema (a steroid given into the pouch) were in remission at 6 weeks. Side effects were reported by 8 of 14 in the metronidazole group and 3 of 12 in the budesonide group.
• In a small trial of rifaximin, an antibiotic that stays mostly in the bowel, 2 of 8 people were in remission at 4 weeks, compared with 0 of 10 given a placebo (very low certainty).
• For chronic pouchitis that does not settle easily, a 2017 meta-analysis of 21 studies found that antibiotics produced remission in 74% of patients and biologic medicines in 53%. Steroids, bismuth, an elemental (liquid) diet and tacrolimus could all induce remission, but not significantly.

The Cochrane review's overall conclusion is that the effects of antibiotics, probiotics and other treatments for treating and preventing pouchitis are uncertain, and that well-designed, adequately sized studies are still needed.

Label safety facts for the two common antibiotics

Neither drug's US label lists pouchitis as an approved use; both are used for it on the basis of the trials above. The ciprofloxacin label carries a boxed warning that fluoroquinolones, including ciprofloxacin, have been linked to disabling and potentially irreversible serious reactions, including tendinitis and tendon rupture, peripheral neuropathy (nerve damage) and central nervous system effects, and that they may worsen muscle weakness in people with myasthenia gravis. The metronidazole label carries a boxed warning that the drug has been shown to cause cancer in mice and rats. These facts matter most for people with antibiotic-dependent pouchitis, who may take antibiotics for long stretches.

Back to Table of Contents

Vedolizumab and the EARNEST Trial

Vedolizumab is a biologic medicine that its US label describes as an integrin receptor antagonist; it acts on a molecule that white blood cells use to enter the lining of the gut. The 2023 review of randomised trials found one trial of it in chronic pouchitis: EARNEST.

The EARNEST trial, published in the New England Journal of Medicine in 2023 and funded by the drug's manufacturer, enrolled 102 adults who had developed chronic pouchitis after a J-pouch for ulcerative colitis. Half were given vedolizumab and half a placebo. The trial gave vedolizumab 300 mg into a vein on day 1 and at weeks 2, 6, 14, 22 and 30, and every participant also took ciprofloxacin during weeks 1 to 4.

• Main result: at week 14, 16 of 51 people (31%) given vedolizumab were in remission on the modified activity index, compared with 5 of 51 (10%) given the placebo, a difference of 21 percentage points.
• Later and other measures: differences in favour of vedolizumab were also seen for remission at week 34 (17 percentage points, with a confidence interval running from 0 to 35, which means the true difference could be close to none), for response at weeks 14 and 34, and for remission on the full index at weeks 14 and 34.
• Safety: serious adverse events occurred in 3 of 51 people (6%) given vedolizumab and 4 of 51 (8%) given the placebo.

The trial shows a real but modest effect: most people in the vedolizumab group were not in remission at week 14. The 2023 review in Alimentary Pharmacology and Therapeutics rated this evidence moderate certainty and concluded that, apart from vedolizumab and one probiotic mixture, the effects of other medical treatments for pouchitis are uncertain.

What the US label says

The current US label lists vedolizumab for adults with moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease; it does not list pouchitis. For those conditions the label gives 300 mg into a vein at weeks 0, 2 and 6, and then every 8 weeks, with an option to switch to injections under the skin after the first two doses. The label carries no boxed warning. It states that progressive multifocal leukoencephalopathy (PML), a rare brain infection, has occurred in people given some integrin-blocking and immune-suppressing products, and that although unlikely, a risk of it with vedolizumab cannot be ruled out. More on how this medicine compares with others is on the biologics page.

Back to Table of Contents

Other Biologic Medicines

Other biologics are used for chronic pouchitis, but almost all of the evidence comes from observational studies rather than placebo-controlled trials.

A 2021 meta-analysis pooled 15 studies of 311 people with chronic antibiotic-refractory pouchitis: 92 treated with infliximab, 42 with adalimumab, 144 with vedolizumab and 33 with ustekinumab. Studies of Crohn's-like disease were left out. The pooled rates were:

• Clinical improvement: 71.4% with infliximab, 58.2% with adalimumab and 47.9% with vedolizumab.
• Clinical remission: 65.7% with infliximab, 31% with adalimumab and 47.4% with vedolizumab.
• Endoscopic findings: endoscopic improvement in 61.2% of people treated with vedolizumab and endoscopic remission in 70.3% treated with infliximab.
• Side effects: adverse events were reported in 3.9% of patients.

These pooled rates come from studies without a placebo group, so they cannot be compared directly with the EARNEST result. The only placebo-controlled trial of a tumor necrosis factor inhibitor in the Cochrane review was very small: 3 of 6 people given adalimumab and 3 of 7 given a placebo improved at 4 weeks (low certainty evidence).

A 2025 review in the Annual Review of Medicine sums up the situation: managing chronic pouchitis is challenging because the evidence is limited and there are few randomised controlled trials.

Back to Table of Contents

What the Probiotic Trials Found

Most of the strong probiotic results come from one high-concentration mixture of eight bacterial strains: four strains of lactobacilli, three of bifidobacteria and one of Streptococcus salivarius subspecies thermophilus. It was tested in three placebo-controlled trials.

• Keeping chronic pouchitis in remission (2000): 40 people with chronic pouchitis, already in remission after antibiotics, were randomised to the mixture or a placebo for 9 months. The trial gave 6 g a day. Three people (15%) in the probiotic group relapsed, compared with 20 (100%) in the placebo group.
• Recurrent or refractory pouchitis (2004): 36 people who had had pouchitis at least twice in the past year, or who needed continuous antibiotics, first took metronidazole and ciprofloxacin together for 4 weeks. Once in remission, 20 were given the mixture once a day and 16 a placebo. At one year, remission was maintained in 17 people (85%) on the probiotic and 1 person (6%) on placebo. Quality-of-life scores stayed high with the probiotic and fell with the placebo.
• Preventing the first episode (2003): 40 people were given the mixture or a placebo for one year, starting right after their temporary ileostomy was closed. Two of 20 (10%) on the probiotic had an episode of acute pouchitis, compared with 8 of 20 (40%) on the placebo.

The reviews grade these results differently. The 2019 Cochrane review pooled the two maintenance trials (34 of 40 versus 1 of 36 staying in remission at 9 to 12 months) and rated the evidence low certainty. The 2023 review rated the same pooled result moderate certainty. Both note that all of the trials were small.

Other single-strain probiotics have weaker or null results. In the Cochrane review, 1 of 10 people given Lactobacillus rhamnosus GG improved at 12 weeks compared with 0 of 10 on placebo; 6 of 7 given Bifidobacterium longum and 3 of 5 given a placebo stayed free of pouchitis at 6 months; and 1 of 9 given Clostridium butyricum stayed free of pouchitis at 24 months, compared with 4 of 8 given a placebo. All of these were rated very low certainty. More background on probiotic strains is on the probiotics page.

The Cochrane review also lists other tested approaches with no clear benefit: allopurinol (43 of 94 people free of pouchitis at 24 months, compared with 39 of 90 on placebo), a bismuth foam enema (9 of 20 improved in each group), and glutamine compared with butyrate (6 of 10 compared with 3 of 9 staying in remission at 3 weeks, very low certainty).

Back to Table of Contents

Stool Transplant Trials

Fecal microbiota transplantation, in which processed stool from a healthy donor is placed in the bowel, is used for recurrent Clostridioides difficile infection (see the fecal microbiota transplant page). If pouchitis were simply a problem of the wrong bacteria, it might be expected to help here too. Two randomised trials found that it did not.

• Finland (2021): 26 people with chronic pouchitis were given donor stool or their own stool (as the placebo) into the pouch at weeks 0 and 4, and followed for 52 weeks. Nine people in the donor group and 8 in the placebo group relapsed, and the time to relapse did not differ significantly. Among people who had been on continuous antibiotics before the study, relapse came sooner with donor stool. No major side effects were reported. The authors concluded that this treatment schedule was not effective.
• Denmark, the MicroPouch trial (2024): 30 people with chronic pouchitis were given stool from four donors, or a placebo, by enema daily for 2 weeks and then every second day for 2 weeks. Enrolment was stopped at 30 people. At 30 days there was no difference in remission (relative risk 1.0). The donor stool did shift participants' gut bacteria toward the donors' bacteria, but it came with more side effects than the placebo (incidence rate ratio 1.67), with no serious side effects in either group.

The 2017 meta-analysis of chronic pouchitis treatments had already noted that stool transplant, in the single study then available, did not achieve remission.

Back to Table of Contents

Crohn's-Like Disease of the Pouch

Some people who had a J-pouch for what was diagnosed as ulcerative colitis later develop inflammation in and around the pouch that looks like Crohn's disease. This is called Crohn's-like disease of the pouch (also Crohn's disease of the pouch). The 2025 review in the Annual Review of Medicine lists it as one of three forms of chronic pouch inflammation, alongside antibiotic-dependent and antibiotic-refractory pouchitis. In the large 3,707-person series from one US centre, 150 people (4%) had Crohn's disease on the final tissue diagnosis after surgery.

Two prospective studies from the same group of US centres have followed people with this condition.

• Real-world remission (2024): of 134 people enrolled, 77 had symptoms at the start. At 12 months, 35 of them were in remission, and most reached it without a change of treatment (12 of the 35 had changed therapy). There was no significant link between changing therapy and remission.
• Ustekinumab compared with tumor necrosis factor inhibitors (2025): among 132 people with chronic pouchitis or Crohn's-like disease starting one of these medicines, 106 (80%) had Crohn's-like disease and 82 (62%) started ustekinumab. In Crohn's-like disease, 62% of people on ustekinumab and 40% of people on a tumor necrosis factor inhibitor were in remission at 6 months. After adjusting for fistulas and the number of earlier advanced medicines, the difference was no longer statistically significant (adjusted odds ratio 1.91, with a confidence interval of 0.69 to 5.30). In chronic pouchitis there was no significant difference between the two medicine types.

The authors describe these results as suggesting a possible benefit of ustekinumab that needs testing in further studies. More on Crohn's disease itself is on the Crohn's disease page.

Back to Table of Contents

Pouch Failure and the Long-Term Outlook

Pouch failure means the pouch has to be removed or permanently bypassed with an ileostomy. Pouchitis is one of several reasons it happens, and the evidence suggests it is a minority cause.

• The 3,707-person series: one US centre followed people who had a first pouch operation between 1984 and 2010. Over a median follow-up of 84 months, pouch failure occurred in 197 people (5.3%); 119 (3.2%) had the pouch removed, 32 (0.8%) had a pouch that was no longer used and 46 (1.2%) had a second pouch built. Leaving pouchitis aside, 29.1% had late complications. Pouch function and quality of life were rated good or excellent in 95%.
• The Danish population study: 32 of 233 people (13.7%) had 36 pouch failures, 6.9% had permanent pouch failure, and 8.3% of the failures were put down to pouchitis. The authors conclude that the overall incidence of pouch failure was low and that pouchitis contributed to a minority of failures. They also found no significant difference in pouchitis between people who had urgent surgery for acute severe ulcerative colitis and those who had planned surgery.
• Primary sclerosing cholangitis: as described above, pouch failure was 10% with this liver disease and 7% without it in the 2021 meta-analysis.

For most people, then, pouchitis is a recurring nuisance that responds to treatment rather than a reason to lose the pouch. For the smaller group with chronic antibiotic-refractory pouchitis or Crohn's-like disease, the evidence base is thin, and the reviews on this page agree that larger, well-designed trials are still needed. The International Ileal Pouch Consortium notes that the condition of a pouch can change over time, which is why its guidelines describe close monitoring and updating of the diagnosis.

Questions about any specific treatment belong with a gastroenterologist or colorectal surgeon who knows the person's history. More about the original disease is on the ulcerative colitis page.

Back to Table of Contents

Key Research Papers

1. Travis S, Silverberg MS, Danese S, Gionchetti P, Löwenberg M, Jairath V, et al. Vedolizumab for the Treatment of Chronic Pouchitis. N Engl J Med. 2023;388(13):1191-1200. PubMed PMID: 36988594
2. Nguyen N, Zhang B, Holubar SD, Pardi DS, Singh S. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2019;11(11):CD001176. PubMed PMID: 31785173
3. Alphonsus L, De Silva TA, Ma C, MacDonald JK, Hanzel J, Beaton M, et al. Systematic review and meta-analysis of randomised controlled trials: Medical therapies for the treatment and prevention of pouchitis. Aliment Pharmacol Ther. 2023;58(3):268-282. PubMed PMID: 37246609
4. Fazio VW, Kiran RP, Remzi FH, Coffey JC, Heneghan HM, Kirat HT, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013;257(4):679-85. PubMed PMID: 23299522
5. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc. 1994;69(5):409-15. PubMed PMID: 8170189
6. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis. 2001;7(4):301-5. PubMed PMID: 11720319
7. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(2):305-9. PubMed PMID: 10930365
8. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124(5):1202-9. PubMed PMID: 12730861
9. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53(1):108-14. PubMed PMID: 14684584
10. Barnes EL, Holubar SD, Herfarth HH. Systematic Review and Meta-analysis of Outcomes After Ileal Pouch-anal Anastomosis in Primary Sclerosing Cholangitis and Ulcerative Colitis. J Crohns Colitis. 2021;15(8):1272-1278. PubMed PMID: 33544128
11. Barnes EL, Allin KH, Iversen AT, Herfarth HH, Jess T. Increasing Incidence of Pouchitis Between 1996 and 2018: A Population-Based Danish Cohort Study. Clin Gastroenterol Hepatol. 2023;21(1):192-199.e7. PubMed PMID: 35525393
12. Bergstrøm R, Lo B, Toft E, Schmidt S, Kaiser S, Kudernatsch R, et al. Incidence and Long-Term Outcomes of Pouchitis in Ulcerative Colitis Patients. United European Gastroenterol J. 2025;13(9):1765-1775. PubMed PMID: 40815573
13. Segal JP, Ding NS, Worley G, Mclaughlin S, Preston S, Faiz OD, et al. Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. Aliment Pharmacol Ther. 2017;45(5):581-592. PubMed PMID: 28008631
14. Chandan S, Mohan BP, Kumar A, Khan SR, Chandan OC, Kassab LL, et al. Safety and Efficacy of Biological Therapy in Chronic Antibiotic Refractory Pouchitis: A Systematic Review With Meta-analysis. J Clin Gastroenterol. 2021;55(6):481-491. PubMed PMID: 34049383
15. Karjalainen EK, Renkonen-Sinisalo L, Satokari R, Mustonen H, Ristimäki A, Arkkila P, et al. Fecal Microbiota Transplantation in Chronic Pouchitis: A Randomized, Parallel, Double-Blinded Clinical Trial. Inflamm Bowel Dis. 2021;27(11):1766-1772. PubMed PMID: 33501942
16. Kousgaard SJ, Cold F, Halkjær SI, Petersen AM, Kjeldsen J, Hansen JM, et al. The Effect of Non-pooled Multidonor Faecal Microbiota Transplantation for Inducing Clinical Remission in Patients with Chronic Pouchitis: Results from a Multicentre, Randomised, Double-blinded, Placebo-controlled Trial [MicroPouch]. J Crohns Colitis. 2024;18(11):1753-1766. PubMed PMID: 38708959
17. Kayal M, Deepak P, Beniwal-Patel P, Raffals L, Dubinsky M, Chang S, et al. Changes in Therapy Are Not Associated With Increased Remission in Patients With Crohn's Disease of the Pouch. Am J Gastroenterol. 2024;119(3):584-587. PubMed PMID: 37975591
18. Barnes EL, Raffals L, Qazi T, Deepak P, Chang S, Beniwal-Patel P, et al. A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the Pouch. Am J Gastroenterol. 2025. Online ahead of print. PubMed PMID: 40560215
19. Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, et al. Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2021;6(10):826-849. PubMed PMID: 34416186
20. Braga-Neto MB, Qazi T, Fulmer C, Holubar SD, Fiocchi C, Ivanov AI, et al. Cellular and molecular mechanisms in the pathogenesis of pouchitis: more than just the microbiota. Gut. 2025;74(11):1905-1915. PubMed PMID: 40240062
21. Meng Z, Yi H, Yu S, Chen J, Sun M. Risk factors for chronic pouchitis in patients with ulcerative colitis following ileal pouch-anal anastomosis: a meta-analysis. Front Med (Lausanne). 2026;13:1886122. PubMed PMID: 42676348
22. Du H, Xiao W, Yin W, Yang X, Fan X, Li B, et al. Risk Factors for Pouchitis After Ileal Pouch-Anal Anastomosis in Ulcerative Colitis Patients. Turk J Gastroenterol. 2026. Online ahead of print. PubMed PMID: 42605211
23. Hata K, Okada S, Shinagawa T, Toshiaki T, Kawai K, Nozawa H. Meta-analysis of the association of extraintestinal manifestations with the development of pouchitis in patients with ulcerative colitis. BJS Open. 2019;3(4):436-444. PubMed PMID: 31463422
24. Abdelrazeq AS, Kandiyil N, Botterill ID, Lund JN, Reynolds JR, Holdsworth PJ, et al. Predictors for acute and chronic pouchitis following restorative proctocolectomy for ulcerative colitis. Colorectal Dis. 2008;10(8):805-13. PubMed PMID: 18005192
25. Kayal M, Boland B. Approach to Therapy for Chronic Pouchitis. Annu Rev Med. 2025;76(1):167-173. PubMed PMID: 39869428
26. Lusetti F, Martins Helfenberger CA, Kurtz de Mello M, Queiroz NSF. Pouchitis unveiled: exploring clinical features, diagnosis, and cutting-edge treatments. Ther Adv Gastroenterol. 2025;18:17562848251316412. PubMed PMID: 39877662

PubMed Topic Searches

1. PubMed: pouchitis randomised controlled trials
2. PubMed: chronic antibiotic-refractory pouchitis
3. PubMed: pouchitis and primary sclerosing cholangitis
4. PubMed: probiotics for pouchitis
5. PubMed: Crohn's-like disease of the pouch
6. PubMed: ileal pouch failure and long-term outcome

Connections

• Inflammatory Bowel Disease (IBD) — the parent topic page
• IBD Surgery Decisions: Resection, J-Pouch and Ostomy — how the pouch is built and staged
• Ulcerative Colitis — the disease that leads most people to a J-pouch
• IBD Biologics: TNF, IL-23 and Integrin Inhibitors — vedolizumab, ustekinumab and the TNF inhibitors in detail
• Primary Sclerosing Cholangitis — the strongest known risk factor for pouchitis
• Crohn's Disease — the background to Crohn's-like disease of the pouch
• IBD Extraintestinal Manifestations — inflammation outside the bowel, a pouchitis risk factor
• Probiotics — background on the bacteria tested in the pouch trials
• Fecal Microbiota Transplant — where stool transplant works, for contrast with pouchitis

Back to Table of Contents

Featured Videos